

Section II (Remarks)**A. Interview with the Examiner**

Applicants wish to thank the Examiner for the helpful interview held on August 18, 2011. During the interview, Applicants' undersigned representative explained that Applicants planned to cancel all claims other than those indicated as allowable on page 1 of the Office Action, and add one claim dependent from Claim 4 that is similar in scope to those claims dependent from allowed Claims 1 and 2. However, it was noted that, while the first page of the Office Action indicated that certain claims were allowable, this was inconsistent with the last sentence on page 6 of the Office Action, which indicated that no claims were allowed. The Examiner agreed that the last sentence on page 6 was erroneous, and that she would so indicate in an Interview Summary. She also agreed that if all of the rejected and withdrawn claims were cancelled, and the only additional claim was the proposed new claim dependent on Claim 4, that the application should proceed to allowance.

B. Summary of Amendment to the Claims

By the present Amendment, Claims 44-49, 53-57, and 59-61 have been cancelled, and new Claim 62 has been added. Claims 1, 2, and 4 were indicated as allowable. Claims 5 and 52 referred to the compositions of Claims 1 and 2, respectively, wherein the unit dosage is a tablet, pill, capsule, or caplet. Claim 62 is a dependent claim from Claim 4, with the same language regarding the unit dosage forms. The addition of this claim adds no new matter.

C. Remarks

1, 2, 4, 5, and 52 were indicated as allowable. All other claims have been cancelled. Claim 62 has been added, as discussed above, to depend from allowable Claim 4.

By cancelling the non-elected claims, and the rejected claims, and pursuing only the allowed claims (with the exception of new Claim 62), it is believed that all rejections have been obviated. Withdrawal of same is respectfully requested.

CONCLUSION

All pending claims are patentably distinguished over the art, and are in form and condition for allowance. The Examiner is encouraged to favorably consider the preceding, and responsively issue a Notice of Allowance.

Respectfully submitted,

/david bradin/

David Bradin

Reg. No. 37,783

Attorney for Applicants

Hultquist IP
Phone: (919) 419-9350
Fax: (919) 419-9354
Attorney File No.: 4354-110

<p>The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284</p>
